Chikungunya Vaccine, Recombinant (Bavarian Nordic)

Chikungunya fever—What we know and have done in the face of a new global public health threat （ 基孔肯雅热——面对这一新的全球公共卫生威胁，我们的所知及所做） Journal of Integrative Medicine 发表。文章对基孔肯雅热进行流行病学分析， 探究了基孔肯雅病毒致病机制与临床转归，总结了目前治疗策略与药物研发前景 ，在此基础上讨论了疫苗研发进展与挑战，并从中医药防治视角与方案， 探讨了借鉴中医药在新冠肺炎防控中积累的经验应用于基孔肯雅热的潜力 河南中医药大学第一附属医院的周荣易教授 研究背景 基孔肯雅热（chikungunya fever）是由基孔肯雅病毒引起，经伊蚊传播的虫媒病毒性疾病，以突发高热、皮疹及严重关节疼痛为主要临床特征 。该疾病已波及全球超119个国家，尤其是在美洲和亚洲地区引发大规模疫情，造成了巨大的疾病负担和经济损失。全球气候变化、城市化进程加速以及人口流动增加，共同导致伊蚊栖息地扩大和病毒适应性增强，使得基孔肯雅热成为一种日益严峻的全球性公共卫生威胁。中国自2008年以来已报告多起输入性病例，广东省在2025年出现了由输入病例引发的本地传播疫情，表明我国同样面临切实的防控压力。 对基孔肯雅热的流行病学、致病机制、疫苗研发及综合防治策略进行全面梳理与展望，具有重要的现实意义。 文章内容 研究团队深入分析了基孔肯雅病毒的病毒学特征，指出其不仅引发急性炎症，还可能通过MXRA8介导的病毒入侵和免疫系统失衡，诱导慢性炎症反应，这是关节长期疼痛和功能障碍的重要机制之一。该综述总结了针对病毒生命周期不同环节的候选药物以及针对宿主免疫反应的免疫调节疗法，并重点评述了目前已获批的减毒活疫苗VLA1553和病毒样颗粒疫苗PXVX0317的高免疫原性、长期安全性及在老年人和免疫功能低下人群中的应用效果。 基孔肯雅病毒（CHIKV）生命周期 此外，该研究从中医药防治视角入手，创新性地将基孔肯雅热纳入中医“湿温疫病”与“痹症”的辨证体系，提出了针对急性期和慢性恢复期的分期论治原则，并探讨了借鉴中医药在新冠肺炎防控中积累的经验并应用于基孔肯雅热的潜力。同时，研究团队强调，如何将中医药理念与现代医学防治策略有机结合，是未来值得深入探索的重要方向。 作者指出，尽管疫苗研发取得实质性进展，但基孔肯雅热在疫苗覆盖、慢性机制研究和综合治疗策略等方面仍面临诸多挑战，未来亟需公共卫生、基础研究、临床医学与传统医学的多学科协作，以应对这一不断扩大的全球健康威胁。 基孔肯雅热（CHIKF）临床表现 小结与展望 该综述系统 揭示了基孔肯雅热传播态势与跨物种机制，深度剖析了其慢性化病理机制，并全面评估了疫苗研发进展和当前挑战 。此外，作者 创新性地提出了中医药防治基孔肯雅热体系构建的概念 ，即通过分析基孔肯雅热的中医辨证分型，实施具体的内服外治方案。 这不仅为西医疗效有限的慢性关节痛提供了补充和替代思路，也体现了“未病先防、既病防变”的中医“治未病”理念在传染病防控中的独特价值。 Yu XL, Zhou RY, Xie XY, Zhang Y, Jia J. Chikungunya fever-What we know and have done in the face of a new global public health threat. J Integr Med . 2026;S2095-4964(26)00040-3. 温馨提示：本文仅为期刊原文的翻译介绍，具体诊疗请遵医嘱，勿自行用药。 Journal of Integrative Medicine （JIM，《结合医学学报（英文）》）创刊于2013年，由上海市教育委员会主管，上海中医药大学主办，主编为海军军医大学凌昌全教授和上海中医药大学季光校长，编辑部位于上海中医药大学附属岳阳中西医结合医院，中国科技出版传媒股份有限公司出版，是一本结合医学领域的国际学术期刊。 JIM秉承着“立足国内、着眼全球”的办刊理念，报道关于补充与替代医学所有方面的高质量文章，例如针灸与传统中医药、阿育吠陀医学、顺势疗法、营养学、脊椎按摩疗法、身心医学、太极、气功、冥想以及任何其他形式的替代医学，致力于成为补充与替代医学领域的国际一流期刊。 JIM目前已被 SCIE、PubMed、ScienceDirect、Scopus、Web of Science、CSCD 等多种国际和国内数据库收录，并曾多次入选“中国最具国际影响力学术期刊”、“中国科技期刊国际影响力提升计划”，2024年度获得“中国科技期刊卓越行动计划二期”项目资助。 影响因子5.2 ，位于JCR分区 Q1 区。 收稿类型 原创论文（临床及基础实验类）、综述（系统性综述、meta分析）、观点等

COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1,058 million, comprised of: DKK 721 million from Travel Health, an increase of 14% compared to the first quarter of 2025 when adjusting for discontinued partnership revenue. The growth was primarily driven by increased demand for rabies vaccines and the continued launch of the chikungunya vaccine. DKK 294 million from Public Preparedness, a decrease of 53% compared to the first quarter of 2025, which is in line with expectations as 2026 is expected to be a normalized year for this business without material impact from mpox outbreaks. DKK 44 million in other revenue. The operating profit (EBITDA) was DKK 165 million, corresponding to an EBITDA margin of 16%. The financial guidance for the full year, which was upgraded on May 11, is maintained at a revenue of DKK 5,500 - 5,700 million and an EBITDA margin of approximately 28%. DKK million Q1 2026 Q1 2025 FY 2026 Guidance Current FY 2026 Guidance Original Revenue 1,058 1,347 5,500 – 5,700 5,000 – 5,200 EBITDA margin 16% 31% ~28% ~25% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Our Travel Health business continues the strong performance, delivering a 14% growth year-over-year, when adjusting for the discontinued partnerships. This underlines our solid focus on organic growth in existing markets, in particular driven by our rabies vaccine, but also by the continued launch of the chikungunya vaccine across new markets. This year, we have launched our vaccine in the Benelux countries, which will be fully onboarded by mid-2026, where also Switzerland will get access to our vaccine after the recent approval by Swissmedic. We also made important advances in our access strategy for the chikungunya vaccine through strategic partnerships in India and Brazil. In our Public Preparedness business, we keep advancing our mpox/smallpox vaccine program and have recently submitted data to EMA to support extension of the approval for children 2-11 years later this year. With our recent contract award from the U.S. government and a broadened customer base, we are well on track to deliver revenue above the communicated base level of DKK 1.5 to 2 billion from this business, despite no expected material impact from outbreaks.” Highlights from the first quarter In January, Bavarian Nordic launched the first tranche of a planned share buy-back program for up to DKK 500 million during 2026. The first tranche comprised a buy-back of shares for up to DKK 150 million and was completed in February. The second tranche of DKK 200 million was initiated in March. The shares will be held as treasury stock for the purpose of adjusting the capital structure. In January, Bavarian Nordic entered into an agreement with Eurofarma, granting them exclusive rights to sell and distribute the Company’s chikungunya vaccine in Brazil. Eurofarma was also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America. In February, Bavarian Nordic announced a new order valued at USD 22.5 million from the Public Health Agency of Canada for the Company’s mpox and smallpox vaccine. In March, Bavarian Nordic announced that the Board of Directors had entered into an agreement with CEO, Paul Chaplin, who will step down. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. In March, Bavarian Nordic announced an expansion of the strategic partnership with Serum Institute of India (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries. In March, Bavarian Nordic submitted clinical data to the European Medicines Agency (EMA) to support the extension of the MVA-BN ® mpox and smallpox vaccine indication to include children aged 2 to 11 years. If successful, approval could be obtained later in 2026. Events after the reporting date In April, the Swiss Agency for Therapeutic Products, Swissmedic, approved Vimkunya ® for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above. Bavarian Nordic expects to launch the vaccine in Switzerland in the second quarter of 2026. In May, Bavarian Nordic completed the second tranche of the planned share buy-back program for 2026. The second tranche comprised a buy-back of shares for DKK 200 million, and, combined with the first tranche, shares of a total aggregate amount of approximately DKK 350 million have now been repurchased during 2026. In May, Bavarian Nordic was awarded additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS ® smallpox vaccine to the U.S. Government. The options will support the manufacturing and supply of freeze-dried JYNNEOS, including manufacturing of additional bulk vaccine necessary for fulfilling the contract. Following this order, the full-year guidance for 2026 was upgraded. Conference call and webcast The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via . To join the Q&A session, please register in advance via . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 Company Announcement no. 24 / 2026 Attachments Bavarian Nordic Q1 2026 Report Bavarian Nordic Announces Interim Results for the First Three Months of 2026